These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 29635721)
21. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989 [TBL] [Abstract][Full Text] [Related]
22. Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing. van den Bersselaar LR; Hellblom A; Gashi M; Kamsteeg EJ; Voermans NC; Jungbluth H; de Puydt J; Heytens L; Riazi S; Snoeck MMJ Anesthesiology; 2022 Jun; 136(6):940-953. PubMed ID: 35285867 [TBL] [Abstract][Full Text] [Related]
23. Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature. Lawal TA; Todd JJ; Witherspoon JW; Bönnemann CG; Dowling JJ; Hamilton SL; Meilleur KG; Dirksen RT Skelet Muscle; 2020 Nov; 10(1):32. PubMed ID: 33190635 [TBL] [Abstract][Full Text] [Related]
25. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met. Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814 [TBL] [Abstract][Full Text] [Related]
26. Risk of malignant hyperthermia in patients carrying a variant in the skeletal muscle ryanodine receptor 1 gene. Janssens L; De Puydt J; Milazzo M; Symoens S; De Bleecker JL; Herdewyn S Neuromuscul Disord; 2022 Dec; 32(11-12):864-869. PubMed ID: 36283893 [TBL] [Abstract][Full Text] [Related]
27. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Zhou H; Jungbluth H; Sewry CA; Feng L; Bertini E; Bushby K; Straub V; Roper H; Rose MR; Brockington M; Kinali M; Manzur A; Robb S; Appleton R; Messina S; D'Amico A; Quinlivan R; Swash M; Müller CR; Brown S; Treves S; Muntoni F Brain; 2007 Aug; 130(Pt 8):2024-36. PubMed ID: 17483490 [TBL] [Abstract][Full Text] [Related]
28. RYR1-Related Myopathies: Clinical, Histopathologic and Genetic Heterogeneity Among 17 Patients from a Portuguese Tertiary Centre. Samões R; Oliveira J; Taipa R; Coelho T; Cardoso M; Gonçalves A; Santos R; Melo Pires M; Santos M J Neuromuscul Dis; 2017; 4(1):67-76. PubMed ID: 28269792 [TBL] [Abstract][Full Text] [Related]
29. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Jungbluth H; Zhou H; Hartley L; Halliger-Keller B; Messina S; Longman C; Brockington M; Robb SA; Straub V; Voit T; Swash M; Ferreiro A; Bydder G; Sewry CA; Müller C; Muntoni F Neurology; 2005 Dec; 65(12):1930-5. PubMed ID: 16380615 [TBL] [Abstract][Full Text] [Related]
31. The utility of electrodiagnostic testing in unprovoked rhabdomyolysis in the era of next-generation sequencing. Skolka MP; Milone M; Litchy WJ; Laughlin RS; Rubin DI; Liewluck T Muscle Nerve; 2024 Aug; 70(2):180-186. PubMed ID: 38533679 [TBL] [Abstract][Full Text] [Related]
33. A case of discordance between genotype and phenotype in a malignant hyperthermia family. Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931 [TBL] [Abstract][Full Text] [Related]
34. Central core disease is due to RYR1 mutations in more than 90% of patients. Wu S; Ibarra MC; Malicdan MC; Murayama K; Ichihara Y; Kikuchi H; Nonaka I; Noguchi S; Hayashi YK; Nishino I Brain; 2006 Jun; 129(Pt 6):1470-80. PubMed ID: 16621918 [TBL] [Abstract][Full Text] [Related]
35. A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility. Taylor A; Lachlan K; Manners RM; Lotery AJ J Clin Neurosci; 2012 Jan; 19(1):65-70. PubMed ID: 22030266 [TBL] [Abstract][Full Text] [Related]
36. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link? Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425 [TBL] [Abstract][Full Text] [Related]
37. Fever-induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Molenaar JP; Voermans NC; van Hoeve BJ; Kamsteeg EJ; Kluijtmans LA; Kusters B; Jungbluth HJ; van Engelen BG Intern Med J; 2014 Aug; 44(8):819-20. PubMed ID: 25081049 [No Abstract] [Full Text] [Related]
38. An RYR1 mutation associated with malignant hyperthermia is also associated with bleeding abnormalities. Lopez RJ; Byrne S; Vukcevic M; Sekulic-Jablanovic M; Xu L; Brink M; Alamelu J; Voermans N; Snoeck M; Clement E; Muntoni F; Zhou H; Radunovic A; Mohammed S; Wraige E; Zorzato F; Treves S; Jungbluth H Sci Signal; 2016 Jul; 9(435):ra68. PubMed ID: 27382027 [TBL] [Abstract][Full Text] [Related]
39. Investigating the genetic susceptibility to exertional heat illness. Gardner L; Miller DM; Daly C; Gupta PK; House C; Roiz de Sa D; Shaw MA; Hopkins PM J Med Genet; 2020 Aug; 57(8):531-541. PubMed ID: 32054689 [TBL] [Abstract][Full Text] [Related]
40. Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. Russell T; Riazi S; Kraeva N; Steel AC; Hawryluck LA Anaesthesia; 2012 Sep; 67(9):1021-4. PubMed ID: 22734812 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]